Obesity & Diabetes Week

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Obesity & Diabetes Week


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Finance

Transdermal drug delivery technology company reports Q3 financial results

For the 3 months ended September 30, 2004, the net loss applicable to common stockholders was $1,302,000, or $.07 per share, as compared to $1,351,000, or $.14 per share, for the same period in 2003. For the 9 months ended September 30, 2004, the net loss applicable to common stockholders was $4,112,000, or $.26 per share, as compared to $3,363,000, or $.36 per share, for the same period in 2003.

Sontra's cash on hand at September 30, 2004 increased by $601,000 from the end of the previous quarter to $6,274,000. During the...

• View Other Issues of Obesity & Diabetes Week
  
• View Other NewsRx Publications